Victor S. Joo

TL;DR: The role of T‐cell exhaustion in HIV disease progression, the long‐term defect of T-cell function even in aviremic patients on antiretroviral therapy (ART), the role of exhaustion‐specific markers in maintaining a reservoir of latently infected cells, and exploiting these markers in HIV cure strategies are discussed.

TL;DR: In this article , the authors describe advances in antibody discovery and engineering that have led to the development of mAbs for use against infections caused by viruses including SARS-CoV-2, respiratory syncytial virus (RSV), Ebola virus (EBOV), human cytomegalovirus (HCMV), and influenza.

TL;DR: In this article, the authors identify non-blocking anti-PD-1 anti-antagonistic antibodies that are able to recognize epitopes on PD-1 located on the opposing face of the PDL-1 interaction and overlap with a newly identified evolutionarily conserved patch.

TL;DR: In this article, B cells from COVID-19 donors and identified P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date.

TL;DR: The imbalance in Th2/Th1-like Tfhs affects B cell responses in viremic HIV infection, and total and HIV-specific CXCR3+ B cells showed lower rate of somatic hypermutation, as compared to CX CR3- B cells.